These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 11251351)
1. Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Dahl OE Haemostasis; 2000; 30 Suppl 2():101-5; discussion 82-3. PubMed ID: 11251351 [TBL] [Abstract][Full Text] [Related]
2. Clinical experience with ximelagatran in orthopaedic surgery. Eriksson B Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625 [TBL] [Abstract][Full Text] [Related]
3. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569 [TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R Arch Intern Med; 2000 Jul; 160(14):2208-15. PubMed ID: 10904465 [TBL] [Abstract][Full Text] [Related]
5. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Kakkar VV; Howes J; Sharma V; Kadziola Z Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310 [TBL] [Abstract][Full Text] [Related]
6. Extended thromboprophylaxis following lower limb arthroplasty: what do the clinical trials mean? Cohen AT; Khushal A Haemostasis; 2000; 30 Suppl 2():88-94; discussion 82-3. PubMed ID: 11251349 [TBL] [Abstract][Full Text] [Related]
7. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement. Bell GK; Goldhaber SZ Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156 [TBL] [Abstract][Full Text] [Related]
8. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Heit JA; Elliott CG; Trowbridge AA; Morrey BF; Gent M; Hirsh J Ann Intern Med; 2000 Jun; 132(11):853-61. PubMed ID: 10836911 [TBL] [Abstract][Full Text] [Related]
9. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty. Whang PG; Lieberman JR Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893 [TBL] [Abstract][Full Text] [Related]
10. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Planès A; Vochelle N; Fagola M; Bellaud M Blood Coagul Fibrinolysis; 1998 Sep; 9(6):499-505. PubMed ID: 9819000 [TBL] [Abstract][Full Text] [Related]
11. New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience. Hull RD Haemostasis; 2000; 30 Suppl 2():95-100; discussion 82-3. PubMed ID: 11251350 [TBL] [Abstract][Full Text] [Related]
12. Orthopaedic surgery as a model for drug development in thrombosis. Dahl OE Drugs; 2004; 64 Suppl 1():17-25. PubMed ID: 15586624 [TBL] [Abstract][Full Text] [Related]
13. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Strebel N; Prins M; Agnelli G; Büller HR Arch Intern Med; 2002 Jul; 162(13):1451-6. PubMed ID: 12090880 [TBL] [Abstract][Full Text] [Related]
15. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J; Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738 [TBL] [Abstract][Full Text] [Related]
16. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317 [TBL] [Abstract][Full Text] [Related]
17. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. Abad JI; Gómez-Outes A; Martínez-González J; Rocha E; Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172 [TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism prophylaxis after hospital discharge: transition to preventive care. Kaatz S; Spyropoulos AC Hosp Pract (1995); 2011 Aug; 39(3):7-15. PubMed ID: 21881387 [TBL] [Abstract][Full Text] [Related]
19. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Hull RD; Pineo GF; Stein PD; Mah AF; MacIsaac SM; Dahl OE; Butcher M; Brant RF; Ghali WA; Bergqvist D; Raskob GE Ann Intern Med; 2001 Nov; 135(10):858-69. PubMed ID: 11712876 [TBL] [Abstract][Full Text] [Related]
20. Thromboembolic disease in hip replacement surgery. Salvati E; Gonzales Della Valle A; Zoppi A; Pavone V Chir Organi Mov; 2005; 90(3):209-28. PubMed ID: 16681100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]